- Home
- GENC vs TARA Comparison
GENC vs TARA Comparison
Compare GENC & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENC | TARA |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.4M | 165.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GENC | TARA |
|---|---|---|
| Price | $13.62 | $5.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $16.00 | ★ $21.00 |
| AVG Volume (30 Days) | 31.6K | ★ 775.6K |
| Earning Date | 12-09-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.92 | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $115,437,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.79 | ★ N/A |
| Revenue Growth | ★ 2.01 | N/A |
| 52 Week Low | $10.80 | $2.77 |
| 52 Week High | $17.40 | $7.82 |
Technical Indicators
Market Signals| Indicator | GENC | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 60.57 | 53.23 |
| Support Level | $13.12 | $5.03 |
| Resistance Level | $13.60 | $5.87 |
| Average True Range (ATR) | 0.44 | 0.29 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 78.33 | 73.20 |
Price Performance
Historical ComparisonAbout GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).